SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
No objection to the use of their data
Patients able to complete an online questionnaire (via the internet)
None
Patients treated with WEGOVY® (semaglutide 2.4 mg) under temporary authorization for use (ATU) and the early access program in France.
Cohort
Prospective
SEMAFOLLOW questionnaire
Other interventionIf the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes
Describe weight changes during the follow-up period according to patient characteristics.
Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.
Compare the profiles of responders and non-responders
Describe weight change according to different subpopulations.
Click on the lead sponsor to view all of their trials.
Nantes University Hospital
Lead sponsor
Novo Nordisk A/S
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
